Endocrinoterapia neoadiuvante nel carcinoma della mammella localmente avanzato

Translated title of the contribution: Aromatase inhibitors in advanced breast cancer

Gian Paolo Spinelli, Federica Tomao, Evelina Miele, Giulia Pasciuti, Michelangelo Russillo, Silverio Tomao

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Benefits from hormonal therapy in patients with hormon-sensitive breast cancers are widely and well known. A great challenge for clinicians is represented by the possibility to use citoreductive primary hormonal therapy in patients with locally advanced breast carcinoma. Five-year treatment with tamoxifen has been for long time the gold standard in adjuvant settings. In post-menopausal women affected by breast cancer larger than 3 cm and expressing estrogen receptors (ER+), clinical trials have shown that few months treatment with aromatase inhibitors can downsizing tumors. This citoreduction is greater than the one obtained with tamoxifen and it makes conservative surgery possible in most part of cases.

Original languageItalian
Pages (from-to)34-38
Number of pages5
JournalRecenti Progressi in Medicina
Volume99
Issue number1
Publication statusPublished - Jan 2008

Fingerprint

Aromatase Inhibitors
Breast Neoplasms
Tamoxifen
Therapeutics
Estrogen Receptors
Clinical Trials
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Spinelli, G. P., Tomao, F., Miele, E., Pasciuti, G., Russillo, M., & Tomao, S. (2008). Endocrinoterapia neoadiuvante nel carcinoma della mammella localmente avanzato. Recenti Progressi in Medicina, 99(1), 34-38.

Endocrinoterapia neoadiuvante nel carcinoma della mammella localmente avanzato. / Spinelli, Gian Paolo; Tomao, Federica; Miele, Evelina; Pasciuti, Giulia; Russillo, Michelangelo; Tomao, Silverio.

In: Recenti Progressi in Medicina, Vol. 99, No. 1, 01.2008, p. 34-38.

Research output: Contribution to journalArticle

Spinelli, GP, Tomao, F, Miele, E, Pasciuti, G, Russillo, M & Tomao, S 2008, 'Endocrinoterapia neoadiuvante nel carcinoma della mammella localmente avanzato', Recenti Progressi in Medicina, vol. 99, no. 1, pp. 34-38.
Spinelli GP, Tomao F, Miele E, Pasciuti G, Russillo M, Tomao S. Endocrinoterapia neoadiuvante nel carcinoma della mammella localmente avanzato. Recenti Progressi in Medicina. 2008 Jan;99(1):34-38.
Spinelli, Gian Paolo ; Tomao, Federica ; Miele, Evelina ; Pasciuti, Giulia ; Russillo, Michelangelo ; Tomao, Silverio. / Endocrinoterapia neoadiuvante nel carcinoma della mammella localmente avanzato. In: Recenti Progressi in Medicina. 2008 ; Vol. 99, No. 1. pp. 34-38.
@article{5399c24c535c475f83127ab3ce47fe10,
title = "Endocrinoterapia neoadiuvante nel carcinoma della mammella localmente avanzato",
abstract = "Benefits from hormonal therapy in patients with hormon-sensitive breast cancers are widely and well known. A great challenge for clinicians is represented by the possibility to use citoreductive primary hormonal therapy in patients with locally advanced breast carcinoma. Five-year treatment with tamoxifen has been for long time the gold standard in adjuvant settings. In post-menopausal women affected by breast cancer larger than 3 cm and expressing estrogen receptors (ER+), clinical trials have shown that few months treatment with aromatase inhibitors can downsizing tumors. This citoreduction is greater than the one obtained with tamoxifen and it makes conservative surgery possible in most part of cases.",
keywords = "Aromatase inhibitors, Locally advanced breast cancer, Neoadjuvant therapy, Tamoxifen",
author = "Spinelli, {Gian Paolo} and Federica Tomao and Evelina Miele and Giulia Pasciuti and Michelangelo Russillo and Silverio Tomao",
year = "2008",
month = "1",
language = "Italian",
volume = "99",
pages = "34--38",
journal = "Recenti Progressi in Medicina",
issn = "0034-1193",
publisher = "Il Pensiero Scientifico Editore s.r.l.",
number = "1",

}

TY - JOUR

T1 - Endocrinoterapia neoadiuvante nel carcinoma della mammella localmente avanzato

AU - Spinelli, Gian Paolo

AU - Tomao, Federica

AU - Miele, Evelina

AU - Pasciuti, Giulia

AU - Russillo, Michelangelo

AU - Tomao, Silverio

PY - 2008/1

Y1 - 2008/1

N2 - Benefits from hormonal therapy in patients with hormon-sensitive breast cancers are widely and well known. A great challenge for clinicians is represented by the possibility to use citoreductive primary hormonal therapy in patients with locally advanced breast carcinoma. Five-year treatment with tamoxifen has been for long time the gold standard in adjuvant settings. In post-menopausal women affected by breast cancer larger than 3 cm and expressing estrogen receptors (ER+), clinical trials have shown that few months treatment with aromatase inhibitors can downsizing tumors. This citoreduction is greater than the one obtained with tamoxifen and it makes conservative surgery possible in most part of cases.

AB - Benefits from hormonal therapy in patients with hormon-sensitive breast cancers are widely and well known. A great challenge for clinicians is represented by the possibility to use citoreductive primary hormonal therapy in patients with locally advanced breast carcinoma. Five-year treatment with tamoxifen has been for long time the gold standard in adjuvant settings. In post-menopausal women affected by breast cancer larger than 3 cm and expressing estrogen receptors (ER+), clinical trials have shown that few months treatment with aromatase inhibitors can downsizing tumors. This citoreduction is greater than the one obtained with tamoxifen and it makes conservative surgery possible in most part of cases.

KW - Aromatase inhibitors

KW - Locally advanced breast cancer

KW - Neoadjuvant therapy

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=40349096325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40349096325&partnerID=8YFLogxK

M3 - Articolo

VL - 99

SP - 34

EP - 38

JO - Recenti Progressi in Medicina

JF - Recenti Progressi in Medicina

SN - 0034-1193

IS - 1

ER -